Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.
AUTOR(ES)
Hedner, U
RESUMO
Two patients with hemophilia A complicated with high-titer alloantibodies have been treated by repeated infusions of microgram quantities of pure human Factor VIIa. Patient 1 was presented with a gastrocnemius muscle bleeding that involved the knee joint. Upon treatment with Factor VIIa the circumference of the muscle decreased and joint mobility increased substantially. Patient 2 was given Factor VIIa concurrent with tranexamic acid in association with the extraction of two primary molars. No significant gingival bleeding occurred after Factor VIIa and tranexamic acid treatment. Furthermore, no deleterious side effects or increase of the alloantibody level were observed in either patient throughout the Factor VIIa infusion. These results, although limited and preliminary in nature, suggest that trace quantities of Factor VIIa can act as a Factor VIII bypassing activity and restore hemostasis in these patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=370389Documentos Relacionados
- Propagation and Purification of High-Titer Human Cytomegalovirus
- Production of high-titer bovine rotavirus with trypsin.
- High-titer packaging cells producing recombinant retroviruses resistant to human serum.
- High-titer replication of nondefective Sendai virus in MDBK cells.
- Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene.